Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 01/27/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 01/13/23 | SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
4 | |
| 01/09/23 | 8-K | Current report filing |
|
   |
24 |
| 12/23/22 | SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
10 | |
| 12/12/22 | 8-K | Current report filing |
|
|
89 |
| 12/08/22 | 8-K | Current report filing |
|
|
26 |
| 12/08/22 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
71 | |
| 12/08/22 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses |
|
13 | |
| 11/10/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
151 |
| 11/10/22 | 8-K | Current report filing |
|
|
31 |
